載入...
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
BACKGROUND: Clinical trials traditionally use time‐to‐first‐event analysis embedded within the composite endpoint of cardiovascular death (CVD), myocardial infarction (MI), or stroke. However, many patients have >1 event, and this approach may not reflect overall experience. We addressed this by...
Na minha lista:
| 發表在: | J Am Heart Assoc |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Blackwell Publishing Ltd
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4310394/ https://ncbi.nlm.nih.gov/pubmed/25012288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001032 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|